327 related articles for article (PubMed ID: 26687159)
1. Integrins and adhesion molecules as targets to treat inflammatory bowel disease.
Bravatà I; Allocca M; Fiorino G; Danese S
Curr Opin Pharmacol; 2015 Dec; 25():67-71. PubMed ID: 26687159
[TBL] [Abstract][Full Text] [Related]
2. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
Bravatà I; Fiorino G; Allocca M; Repici A; Danese S
Scand J Gastroenterol; 2015 Jan; 50(1):113-20. PubMed ID: 25523561
[TBL] [Abstract][Full Text] [Related]
3. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab for the treatment of inflammatory bowel disease.
Haddley K
Drugs Today (Barc); 2014 Apr; 50(4):309-19. PubMed ID: 24918648
[TBL] [Abstract][Full Text] [Related]
6. [New molecules in the treatment of inflammatory bowel disease].
Chaparro M; Gisbert JP
Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
8. Introducing vedolizumab to clinical practice: who, when, and how?
Bryant RV; Sandborn WJ; Travis SP
J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
[TBL] [Abstract][Full Text] [Related]
9. Biological therapies for inflammatory bowel disease: research drives clinics.
Danese S; Semeraro S; Armuzzi A; Papa A; Gasbarrini A
Mini Rev Med Chem; 2006 Jul; 6(7):771-84. PubMed ID: 16842127
[TBL] [Abstract][Full Text] [Related]
10. Anti-adhesion molecules: is gut specificity the key for a good safety profile?
Allen PB
Curr Drug Deliv; 2012 Jul; 9(4):333-7. PubMed ID: 22762276
[TBL] [Abstract][Full Text] [Related]
11. New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
van Langenberg DR
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():10-1. PubMed ID: 26990680
[No Abstract] [Full Text] [Related]
12. Targeting integrins and adhesion molecules to combat inflammatory bowel disease.
Marafini I; Sedda S; Pallone F; Monteleone G
Inflamm Bowel Dis; 2014 Oct; 20(10):1885-9. PubMed ID: 25215614
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Immunotherapy; 2019 May; 11(7):565-575. PubMed ID: 30860423
[TBL] [Abstract][Full Text] [Related]
14. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
15. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
17. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.
Holleran G; Lopetuso L; Petito V; Graziani C; Ianiro G; McNamara D; Gasbarrini A; Scaldaferri F
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934123
[TBL] [Abstract][Full Text] [Related]
18. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
Front Immunol; 2018; 9():1700. PubMed ID: 30131801
[TBL] [Abstract][Full Text] [Related]
19. IBD in 2013: enriching the therapeutic armamentarium for IBD.
Danese S; Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol; 2014 Feb; 11(2):84-6. PubMed ID: 24366229
[TBL] [Abstract][Full Text] [Related]
20. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
